Tadekinig Alfa for CAR T Cell Side Effects
This study is testing Tadekinig alfa (IL-18BP) as a rescue treatment for serious side effects that can happen after CAR T cell therapy. These side effects include Cytokine Release Syndrome (CRS) and HLH-like syndrome (CRHLS), which are severe inflammatory reactions. Tadekinig alfa works by blocking a protein called IL-18, which is involved in these inflammatory conditions. The study will look at how safe Tadekinig alfa is and how practical it is to use in about 10 adult patients (18 years or older) who are already part of a CAR T cell clinical trial at the University of Pennsylvania. The main goal is to see if this treatment is safe and feasible within 28 days of starting it.
- Study design
- This is a pilot, open-label study, meaning both you and your doctors will know you are receiving Tadekinig alfa. It plans to enroll about 10 participants.
- What's involved
- You would receive Tadekinig alfa as an injection under the skin, with injection sites rotated. You must already be enrolled in a University of Pennsylvania-sponsored CAR T cell clinical trial. If you can become pregnant, you must agree to use acceptable birth control.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary safety and feasibility will be evaluated at 28 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
At a glance
Conditions
NCT05306080
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Pennsylvania
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluate preliminary safety and feasibility of administering investigational rescue therapies for the treatment of CAR T cell related CRS and CRHLS.28 days
Type, frequency, and severity of AEs/SAEs determined to be related to the rescue therapy.